2-乙基硫代烟酸 | 27868-76-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-乙基硫代烟酸
• 中文别名: 2-(乙基硫代)烟酸
• 英文名称: 2-ethylsulfanylnicotinic acid
• 英文别名: Ethylthio-2-nicotinsaeure；2-(Ethylthio)nicotinic acid；2-ethylsulfanylpyridine-3-carboxylic acid
• CAS: 27868-76-4
• 化学式: C₈H₉NO₂S
• mdl: MFCD00051680
• 分子量: 183.231
• InChiKey: LYHPPDODTUEXAN-UHFFFAOYSA-N

物化性质

• 熔点：
  185 °C
• 稳定性/保质期：
  避免接触强氧化剂

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  75.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

SDS

Name:	2-(Ethylthio)nicotinic acid 97% Material Safety Data Sheet
Synonym:	2-(Ethylthio)pyridine-3-carboxylic aci
CAS:	27868-76-4

Section 1 - Chemical Product MSDS Name:2-(Ethylthio)nicotinic acid 97% Material Safety Data Sheet
Synonym:2-(Ethylthio)pyridine-3-carboxylic aci

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
27868-76-4	2-(Ethylthio)nicotinic acid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 27868-76-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 185 - 187 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H9NO2S
Molecular Weight: 183

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 27868-76-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(Ethylthio)nicotinic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 27868-76-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 27868-76-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 27868-76-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-3-{[1-(4-cyanobenzyl)-1H-imidazol-5-ylmethyl]amino}pyrrolidine hydrochloride 、 2-乙基硫代烟酸 在 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 1-羟基苯并三唑一水物 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 4-(5-{[(S)-1-(2-Ethylsulfanyl-pyridine-3-carbonyl)-pyrrolidin-3-ylamino]-methyl}-imidazol-1-ylmethyl)-benzonitrile
  参考文献：
  名称：

  Design and Biological Activity of (S)-4-(5-{[1-(3-Chlorobenzyl)-2- oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-Aminopyrrolidinone Farnesyltransferase Inhibitor with Excellent Cell Potency

  摘要：

  The synthesis, structure-activity relationships, and biological properties of a novel series of imidazole-containing inhibitors of farnesyltransferase are described. Starting from a 3-amino-pyrrolidinone core, a systematic series of modifications provided 5h, a non-thiol, non-peptide farnesyltransferase inhibitor with excellent bioavailability in dogs. Compound 5h was found to have an unusually favorable ratio of cell potency to intrinsic potency, compared with other known FTIs. It exhibited excellent potency against a range of tumor cell lines in vitro and showed full efficacy in the K-rasB transgenic mouse model.

  DOI：

  10.1021/jm010156p
• 作为产物：
  描述：

  2-巯基烟酸 、 溴乙烷 以to obtain the title compound (1.9 g, 80%)的产率得到2-乙基硫代烟酸
  参考文献：
  名称：

  THIOARYL DERIVATIVES AS GPR120 AGONISTS

  摘要：

  本发明涉及公式1中定义的硫代芳基衍生物，其制备方法，包含其的药物组合物以及使用方法。本发明中的公式1中的硫代芳基衍生物能够促进胃肠道中的GLP-1形成，并通过抗炎作用改善巨噬细胞、胰腺细胞等的胰岛素抵抗力，因此可以有效用于预防或治疗糖尿病、糖尿病并发症、炎症、肥胖症、非酒精性脂肪肝、脂肪性肝炎或骨质疏松症。

  公开号：

  US20150291527A1

文献信息

• Dioxanes and uses thereof
  申请人：——

  公开号：US20040072849A1

  公开（公告）日：2004-04-15

  In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): 1 and pharmaceutically acceptable derivatives thereof, wherein R 1 , R 2 , R 3 , n, X and Y are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The present invention further provides compounds capable of inhibiting histone deacetylatase activity and methods for treating disorders regulated by histone deacetylase activity (e.g., cancer and protozoal infections) comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof. The present invention additionally provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p. The present invention also provides methods for preparing compounds of the invention.

  鉴于需要开发新型治疗剂和有效的合成方法，本发明提供了一般式(I)的新化合物： 1 及其药学上可接受的衍生物，其中R 1 ，R 2 ，R 3 ，n，X和Y如本文所定义。本发明还提供了包含一种式(I)化合物和药学上可接受的载体的药物组合物。本发明还提供了能够抑制组蛋白去乙酰化酶活性的化合物以及治疗由组蛋白去乙酰化酶活性调节的疾病的方法（例如，癌症和原虫感染），包括向需要的受体施用一种式(I)化合物的治疗有效量。本发明还提供了调节Ure2p下游葡萄糖敏感基因子集的方法。本发明还提供了制备本发明化合物的方法。
• [EN] DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE DIAZEPINOINDOLE EN TANT QU'INHIBITEURS DE KINASE
  申请人：PFIZER

  公开号：WO2004063198A1

  公开（公告）日：2004-07-29

  Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions, such as cancers.

  蛋白激酶，如CHK-1，抑制以下式的三环化合物（其中R2、R3和R4如规范中定义）的药物组合物，含有所述化合物或其盐的有效量，可用作单一药剂或与抗肿瘤药剂或具有抗肿瘤效果的治疗放射剂结合，用于治疗疾病或病况，如癌症。
• [EN] THIOARYL DERIVATIVES AS GPR120 AGONISTS<br/>[FR] DÉRIVÉS DE THIOARYLE À TITRE D'AGONISTES DE GPR120
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2014069963A1

  公开（公告）日：2014-05-08

  The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

  本发明涉及规范中定义的Formula 1的硫代芳基衍生物，一种制备该衍生物的方法，包含该衍生物的药物组合物以及其用途。根据本发明，Formula 1的硫代芳基衍生物促进胃肠道中GLP-1的形成，并通过抗炎作用改善巨噬细胞、胰腺细胞等的胰岛素抵抗，因此可以有效用于预防或治疗糖尿病、糖尿病并发症、炎症、肥胖、非酒精性脂肪肝、脂肪性肝炎或骨质疏松症。
• Diacyl derivatives of propylene diamine having herbicidal activity
  申请人：——

  公开号：US20020052295A1

  公开（公告）日：2002-05-02

  Novel herbicidal compounds are provided having the formula (I) 1 wherein one of R 1a and R 1b is a methyl, hydroxymethyl or monohalomethyl group and the other is hydrogen; R 2 is a group R 3 —(X 1 ) m — where X 1 is a methylene, oxy or thio linkage, m is 0 or 1, and R 3 is a substituted phenyl group of formula 2 where R A 2 is a hydrogen, halogen or methyl group and R A 3 is a halogen or halomethyl group; and R 4 is an &agr;-halo- or &agr;,&agr;-dihalo-(C 1-3 )alkyl group or a group having the formula —(X 2 ) n —R 5 where X 2 is a methylene, oxy or thio linkage, n is 0 or 1, and R 5 is an optionally substituted five-member or six-member aromatic or heterocyclic ring.

  提供了一种新的除草化合物，其化学式为(I)，其中R1a和R1b中的一个是甲基、羟甲基或单卤甲基基团，另一个是氢；R2是一个基团R3—(X1)m—，其中X1是一个亚甲基、氧或硫连接，m为0或1，R3是一个取代苯基的化合物，其化学式为，其中RA2是氢、卤素或甲基基团，RA3是卤素或卤甲基基团；R4是一个α-卤代或α，α-二卤代-(C1-3)烷基基团或一个具有化学式—(X2)n—R5的基团，其中X2是一个亚甲基、氧或硫连接，n为0或1，R5是一个可选择取代的五元或六元芳香或杂环环。
• HISTONE DEACETYLASE INHIBITORS
  申请人：Bradner James Elliot

  公开号：US20100056588A1

  公开（公告）日：2010-03-04

  In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.

  为了开发新型治疗剂，本发明提供了新型组蛋白去乙酰化酶抑制剂。这些化合物包括酯键，使它们对酯酶的失活敏感。因此，这些化合物在治疗皮肤疾病方面特别有用。当这些化合物进入血液循环时，酯酶或具有酯酶活性的酶将其裂解成生物学上不活性的碎片或具有大大降低活性的碎片。理想情况下，这些降解产物表现出短的血清和/或系统半衰期，并迅速被排出体外。这些化合物及其制剂在治疗切除性T细胞淋巴瘤、神经纤维瘤、银屑病、脱发、皮肤色素沉着和皮炎等方面特别有用。本发明还提供了制备本发明化合物及其中间体的方法。